Determining your caffeine metabolism phenotype may warrant consideration if cardiovascular risk is a clinical concern. The CYP1A2 rs762551 polymorphism classifies individuals as fast metabolisers (3-hour half-life, 45% frequency), intermediate metabolisers (6–10 hour half-life, 44% frequency), or slow metabolisers (6–10 hour half-life, 11% frequency). For slow metabolisers, the evidence is clear: consuming 4 or more daily cups correlates with 64% increased nonfatal MI risk. Age further modulates this association, with individuals under 59 facing compounded risk. Patients with hypertension, family history of early coronary disease, or arrhythmia susceptibility represent candidates for CYP1A2 testing. Fast metabolisers can consume coffee without demonstrated cardiac penalty. This genetic insight enables truly personalized beverage recommendations based on biology rather than population-level generalizations.
Was this article helpful?
